Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-24 4:38 pm Purchase | 2026-02-17 | 13G | Immunic, Inc. IMUX | Commodore Capital LP | 13,350,121 9.900% | 13,350,121 (New Position) | Filing History |
| 2026-02-17 4:42 pm Sale | 2025-12-31 | 13G | Cogent Biosciences, Inc. COGT | Commodore Capital LP | 2,802,905 1.800% | -7,405,155 (-72.54%) | Filing History |
| 2026-02-17 4:35 pm Sale | 2025-12-31 | 13G | Perceptive Capital Solutions Corp Class A Ordinary Shares PCSC | Commodore Capital LP | 0 0.000% | -750,000 (Position Closed) | Filing History |
| 2026-02-17 4:29 pm Sale | 2025-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN | Commodore Capital LP | 1,475,000 1.400% | -4,225,000 (-74.12%) | Filing History |
| 2026-02-17 4:26 pm Purchase | 2025-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN | Commodore Capital LP | 4,383,508 9.900% | 2,015,624 (+85.12%) | Filing History |
| 2026-02-17 4:22 pm Sale | 2025-12-31 | 13G | Bright Minds Biosciences Inc. DRUG | Commodore Capital LP | 18,851 0.300% | -481,149 (-96.23%) | Filing History |
| 2026-02-17 4:21 pm Purchase | 2025-12-31 | 13G | Definium Therapeutics, Inc. DFTX | Commodore Capital LP | 7,428,775 7.200% | 7,428,775 (New Position) | Filing History |
| 2026-02-17 4:13 pm Purchase | 2025-12-31 | 13G | Alto Neuroscience, Inc. ANRO | Commodore Capital LP | 3,245,628 9.900% | 55,361 (+1.74%) | Filing History |
| 2026-02-09 4:40 pm Purchase | 2026-02-02 | 13G | Perspective Therapeutics, Inc. CATX | Commodore Capital LP | 11,939,753 9.900% | 8,589,753 (+256.41%) | Filing History |
| 2026-01-16 4:23 pm Purchase | 2026-01-09 | 13G | Century Therapeutics, Inc. IPSC | Commodore Capital LP | 13,043,478 7.100% | 13,043,478 (New Position) | Filing History |
| 2025-11-17 5:39 pm Purchase | 2025-11-10 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Commodore Capital LP | 5,650,000 5.100% | 5,650,000 (New Position) | Filing History |
| 2025-11-14 5:17 pm Sale | 2025-09-30 | 13G | Viridian Therapeutics, Inc. VRDN | Commodore Capital LP | 3,200,000 3.900% | -1,100,000 (-25.58%) | Filing History |
| 2025-11-14 5:08 pm Sale | 2025-09-30 | 13G | Celldex Therapeutics, Inc. CLDX | Commodore Capital LP | 3,028,335 4.600% | -321,665 (-9.60%) | Filing History |
| 2025-11-14 5:02 pm Sale | 2025-09-30 | 13G | Nurix Therapeutics, Inc. NRIX | Commodore Capital LP | 3,780,055 4.900% | -69,945 (-1.82%) | Filing History |
| 2025-11-14 4:57 pm Purchase | 2025-09-30 | 13G | Cogent Biosciences, Inc. COGT | Commodore Capital LP | 10,208,060 7.200% | 3,800,000 (+59.30%) | Filing History |
| 2025-11-14 4:51 pm Purchase | 2025-09-30 | 13G | Terns Pharmaceuticals, Inc. TERN | Commodore Capital LP | 5,700,000 6.500% | 1,050,000 (+22.58%) | Filing History |
| 2025-11-14 4:39 pm Sale | 2025-09-30 | 13G | Cidara Therapeutics, Inc. CDTX | Commodore Capital LP | 585,000 2.000% | -590,000 (-50.21%) | Filing History |
| 2025-11-14 4:35 pm Purchase | 2025-09-30 | 13G | Tyra Biosciences, Inc. TYRA | Commodore Capital LP | 3,375,000 6.300% | 625,000 (+22.73%) | Filing History |
| 2025-11-14 4:30 pm Purchase | 2025-09-30 | 13G | Relay Therapeutics, Inc. RLAY | Commodore Capital LP | 17,000,000 9.900% | 3,650,000 (+27.34%) | Filing History |
| 2025-10-27 4:02 pm Purchase | 2025-10-20 | 13G | Alto Neuroscience, Inc. ANRO | Commodore Capital LP | 3,190,267 9.800% | 3,190,267 (New Position) | Filing History |